Date: 2020-06-16
Type of information: Series B financing round
Company: eTheRNA (Belgium)
Investors: LSP (the Netherlands), PMV (Belgium), Boehringer Ingelheim Venture Fund (Germany), Fund+ (Belgium), Omega Funds (USA), Grand Decade, a BVI subsidiary owned by China Grand Pharmaceutical and Healthcare Holdings Ltd; BNP Paribas Fortis Private Equity (Belgium), Yijing Capital (China), Novalis LifeSciences LLC (USA).
Amount: €34 M
Funding type: series B financing round
Planned used:
Others:
- On June 16, 2020, eTheRNA immunotherapies NV, a clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, announced that it has successfully raised €34 million in a Series B equity financing round. All existing investors - LSP (the Netherlands), PMV (Belgium), Boehringer Ingelheim Venture Fund (Germany), Fund+ (Belgium) and Omega Funds (USA) - are participating in the round. They are joined by Grand Decade, a BVI subsidiary owned by China Grand Pharmaceutical and Healthcare Holdings Ltd ('GP(HK)'; HKSE Stock code 00512), BNP Paribas Fortis Private Equity (Belgium), Yijing Capital (China) and Novalis LifeSciences LLC (USA).
GP(HK) and eTheRNA have also agreed outline terms for a possible exclusive strategic partnership for mRNA manufacturing, independent research and development, production and commercialization in Greater China.
Therapeutic area: Immunological diseases - Infectious diseases
Is general: Yes